FindTrial
Sign In

MLN4924

DRUG8 trials

Sponsors

Millennium Pharmaceuticals, Inc., National Cancer Institute (NCI)

Conditions

Acute Lymphoblastic LeukemiaAcute Myelogenous LeukemiaAdvanced Nonhematologic MalignanciesAdvanced Solid TumorsDiffuse, Large B-cell LymphomaHematologic MalignanciesHodgkin LymphomaLarge-Cell Lymphoma, Diffuse

Phase 1

Study of MLN4924 in Adult Patients With Nonhematologic Malignancies
CompletedNCT00677170
Millennium Pharmaceuticals, Inc.Advanced Nonhematologic Malignancies
Start: 2008-04-30End: 2012-12-31Updated: 2013-07-16
Study of MLN4924, a Novel Inhibitor of Nedd8 Activating Enzyme, in Adult Patients With Lymphoma or Multiple Myeloma
CompletedNCT00722488
Millennium Pharmaceuticals, Inc.Hematologic Malignancies, Hodgkin Lymphoma, Lymphoma +1
Start: 2008-06-30End: 2013-09-30Updated: 2013-11-18
MLN4924 for the Treatment of Acute Myelogenous Leukemia, Myelodysplastic Syndrome, and Acute Lymphoblastic Leukemia
CompletedNCT00911066
Millennium Pharmaceuticals, Inc.Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia, Myelodysplastic Syndrome
Start: 2009-06-30End: 2013-10-31Updated: 2013-12-05
Dose Escalation Study of MLN4924 in Adults With Melanoma
CompletedNCT01011530
Millennium Pharmaceuticals, Inc.Metastatic Melanoma
Start: 2009-12-31End: 2013-01-31Updated: 2013-07-16
MLN4924 Compared With MLN4924 Plus Chemotherapy for Large B-cell Lymphoma
WithdrawnNCT01415765
National Cancer Institute (NCI)Diffuse, Large B-cell Lymphoma, Large-Cell Lymphoma, Diffuse, Lymphoma, Diffuse Large-Cell +1
Start: 2011-07-15End: 2014-01-07Updated: 2019-12-17
Study of MLN4924 Plus Azacitidine in Treatment-naive Participants With Acute Myelogenous Leukemia (AML) Who Are 60 Years or Older
CompletedNCT01814826
Millennium Pharmaceuticals, Inc.Acute Myelogenous Leukemia
Start: 2013-04-10End: 2018-04-08Updated: 2020-03-03
Dose Escalation, Multi-arm Study of MLN4924 Plus Docetaxel, Gemcitabine, or Combination of Carboplatin and Paclitaxel in Participants With Solid Tumors
CompletedNCT01862328
Millennium Pharmaceuticals, Inc.Solid Tumors
Start: 2013-06-10End: 2018-05-21Updated: 2020-06-22
Effects of Fluconazole and Itraconazole CYP3A-Mediated Inhibition on the Pharmacokinetics, Safety, and Tolerability of MLN4924 in Participants With Advanced Solid Tumors
CompletedNCT02122770
Millennium Pharmaceuticals, Inc.Advanced Solid Tumors
Start: 2014-04-01End: 2017-06-05Updated: 2019-01-07

Related Papers

Model-based analysis to support dose selection of pevonedistat (PEV) combined with azacitidine (AZA) in patients (pts) with higher-risk myelodysplastic syndromes (MDS)/chronic myelomonocytic leukemia (CMML) and acute myeloid leukemia (AML).
Journal of Clinical Oncology2021-05-201 citations
Pevonedistat-Azacitidine for Myeloid-Based Malignancies
Oncology Times2021-05-20
Phase Ib study of pevonedistat, a NEDD8-activating enzyme inhibitor, in combination with docetaxel, carboplatin and paclitaxel, or gemcitabine, in patients with advanced solid tumors.
2018-05-2164 citations
Pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, combined with azacitidine in patients with AML
Blood2018-01-18198 citations
Results of a Clinical Study of Pevonedistat (Pev), a First-in-Class NEDD8-Activating Enzyme (NAE) Inhibitor, Combined with Azacitidine (Aza) in Older Patients (Pts) with Acute Myeloid Leukemia (AML)
Blood2016-12-029 citations
Investigational NEDD8-activating enzyme inhibitor pevonedistat (Pev) plus chemotherapy in patients (Pts) with solid tumors (Phase 1b study): Antitumor activity of pev plus carboplatin (Carbo)/paclitaxel (Pac).
Journal of Clinical Oncology2016-05-202 citations
Abstract C55: Nedd8-activating enzyme inhibitor pevonedistat synergizes with cisplatin and carboplatin through interference with nucleotide excision repair and interstrand cross-link repair mechanisms in non-small cell lung cancer
Molecular Cancer Therapeutics2015-12-012 citations
Abstract B26: Phase 1b trial of investigational NEDD8-activating enzyme (NAE) inhibitor pevonedistat (TAK-924/MLN4924) in combination with docetaxel, paclitaxel/carboplatin, or gemcitabine in patients (pts) with solid tumors
Molecular Cancer Therapeutics2015-12-01
MLN4924, a Novel Investigational Inhibitor Of NEDD8-Activating Enzyme (NAE), In Adult Patients With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS): Results From Multiple Dosing Schedules In a Phase 1 Study
Blood2013-11-155 citations
Abstract B92: Nedd8-activating enzyme inhibitor MLN4924 provides synergy in nonclinical models with mitomycin C through interactions with ATR, BRCA1/BRCA2 and chromatin dynamics pathways.
Molecular Cancer Therapeutics2013-11-01